MAZE
Income statement / Annual
Last year (2024), Maze Therapeutics, Inc.'s total revenue was $167.50 M,
and the percentage change from the previous year is not available.
In 2024, Maze Therapeutics, Inc.'s net income was $52.23 M.
See Maze Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$167.50 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$167.50 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
| Research and Development Expenses |
$83.50 M
|
$73.95 M
|
$88.19 M
|
| General & Administrative Expenses |
$26.42 M
|
$24.61 M
|
$22.83 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.42 M
|
$24.61 M
|
$22.83 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$109.91 M
|
$98.55 M
|
$111.03 M
|
| Cost And Expenses |
$109.91 M
|
$98.55 M
|
$111.03 M
|
| Interest Income |
$4.65 M
|
$1.97 M
|
$2.03 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.30 M
|
$4.09 M
|
$3.82 M
|
| EBITDA |
$60.88 M |
-$94.46 M |
-$107.21 M |
| EBITDA Ratio |
0.36
|
0
|
0
|
| Operating Income Ratio |
0.34
|
0
|
0
|
| Total Other Income/Expenses Net |
-$4.18 M
|
-$1.86 M
|
-$3.91 M
|
| Income Before Tax |
$53.40 M
|
-$100.42 M
|
-$114.94 M
|
| Income Before Tax Ratio |
0.32
|
0
|
0
|
| Income Tax Expense |
$1.17 M
|
$0.00
|
$0.00
|
| Net Income |
$52.23 M
|
-$100.42 M
|
-$114.94 M
|
| Net Income Ratio |
0.31
|
0
|
0
|
| EPS |
0.0778 |
-2.2938 |
-2.6256 |
| EPS Diluted |
0.0778 |
-2.2938 |
-2.6256 |
| Weighted Average Shares Out |
$43.80 M
|
$43.78 M
|
$43.78 M
|
| Weighted Average Shares Out Diluted |
$43.80 M
|
$43.78 M
|
$43.78 M
|
| Link |
|
|
|
